

PRESS RELEASE

innate pharma

INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON JUNE 28, 2013, IN MARSEILLE, FRANCE

Marseille, France, May 28, 2013

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 28, 2013, at 9:30 am in its headquarters, 117 avenue de Luminy, F-13009 Marseille.

The Notice of Meeting of this AGM was published on May 24, 2013 in the French official legal bulletin (“BALO”). The documentation regarding this AGM is made available to shareholders in accordance with existing regulations and on the [Company’s website](#).

Precision regarding the AGM:


Only shareholders having registered their shares at least three business days prior to the date of the AGM, by midnight Paris time, will be able to attend.

Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by mail. The “attestation de participation” may replace the admission card for shareholders wishing to attend the AGM in person.

Written questions from shareholders must be received from the day of the publication of the official Notice of Meeting of the AGM up until four business days prior to the AGM:

- by registered letter, addressed to Innate Pharma, Shareholders Services, 117 avenue de Luminy, BP 30191, F-13009 Marseille, France or
- by e-mail to investors@innate-pharma.com.

Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French “Code de Commerce”) by sending a request by regular mail or e-mail to the above mentioned addresses.



PRESS RELEASE

innate pharma

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 83 employees as at March 31, 2013.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma

Laure-Hélène Mercier
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
investors@innate-pharma.com

ATCG Press

Marielle Bricman
Mob.: +33 (0)6 26 94 18 53
mb@atcg-partners.com